Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Suzuki, Ayako ^a   Mimaki, Sachiyo ^b   Yamane, Yuki ^b   Kawase, Akikazu ^b   Matsushima, Koutatsu ^b   Suzuki, Makito ^b   Goto, Koichi ^b   Sugano, Sumio ^a   Esumi, Hiroyasu ^b   Suzuki, Yutaka ^a   Tsuchihara, Katsuya ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; ATM GENE; CANCER PROGNOSIS; CAUCASIAN; COL22A GENE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DNAH7 GENE; EGFR GENE; ETHNIC DIFFERENCE; EXOME; FEMALE; FER1L6 GENE; FSTL5 GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; JAPANESE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NRXN3 GENE; ONCOGENE; ONCOGENE K RAS; PAPPA2 GENE; PREX1 GENE; PREX2 GENE; SEQUENCE ANALYSIS; SOMATIC MUTATION; TNN GENE; TP53 GENE;

ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION;

EID: 84884188147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073484     Document Type: Article

References (52)

1. The 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061-1073. doi:10.1038/nature09534. PubMed: 20981092.
2. The 1000 Genomes Project Consortium (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56-65. doi:10.1038/nature11632. PubMed: 23128226.
3. Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, et al. (2009) Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A 106: 19096-19101. doi:10.1073/pnas.0910672106. PubMed: 19861545.
4. Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, et al. (2009) Targeted capture and massively parallel sequencing of 12 human exomes. Nature 461: 272-276. doi:10.1038/nature08250. PubMed: 19684571.
5. Clark MJ, Chen R, Lam HY, Karczewski KJ, Chen R, et al. (2011) Performance comparison of exome DNA sequencing technologies. Nat Biotechnol 29: 908-914. doi:10.1038/nbt.1975. PubMed: 21947028.
6. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, et al. (2011) Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 12: 745-755. doi:10.1038/nrg3031. PubMed: 21946919.
7. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, et al. (2010) Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 42: 30-35. doi:10.1038/ng.499. PubMed: 19915526.
8. Biesecker LG, (2010) Exome sequencing makes medical genomics a reality. Nat Genet 42: 13-14. doi:10.1038/ng0110-13. PubMed: 20037612.
9. Louis-Dit-Picard H, Barc J, Trujillano D, Miserey-Lenkei S, Bouatia-Naji N, et al. (2012) KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet.
10. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, et al. (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311. doi:10.1093/nar/29.1.308. PubMed: 11125122.
11. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. (2004) A census of human cancer genes. Nat Rev Cancer 4: 177-183. doi:10.1038/nrc1299. PubMed: 14993899.
12. International Cancer Genome Consortium (2010) International network of cancer genome projects. Nature 464: 993-998. doi:10.1038/nature08987. PubMed: 20393554.
13. Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, et al. (2011) High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 43: 464-469. doi:10.1038/ng.804. PubMed: 21499249.
14. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, et al. (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488: 100-105. doi:10.1038/nature11284. PubMed: 22832583.
15. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615. doi:10.1038/nature10166. PubMed: 21720365.
16. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404. PubMed: 22722201.
17. The Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature.
18. The Cancer Genome Atlas Research Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337. doi:10.1038/nature11252. PubMed: 22810696.
19. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, et al. (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150: 1107-1120. doi:10.1016/j.cell.2012.08.029. PubMed: 22980975.
20. Davies H, Hunter C, Smith R, Stephens P, Greenman C, et al. (2005) Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591-7595. PubMed: 16140923.
21. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075. doi:10.1038/nature07423. PubMed: 18948947.
22. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869-873. doi:10.1038/nature09208. PubMed: 20668451.
23. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, et al. (2008) The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet Chapter 10: Unit 10.11: PubMed: 18428421.
24. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-D950. doi:10.1093/nar/gkq929. PubMed: 20952405.
25. Li H, Durbin R, (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760. doi:10.1093/bioinformatics/btp324. PubMed: 19451168.
26. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297-1303. doi:10.1101/gr.107524.110. PubMed: 20644199.
27. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, et al. (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43: 491-498. doi:10.1038/ng.806. PubMed: 21478889.
28. Welch HC, Coadwell WJ, Ellson CD, Ferguson GJ, Andrews SR, et al. (2002) P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 108: 809-821. doi:10.1016/S0092-8674(02)00663-3. PubMed: 11955434.
29. Rosenfeldt H, Vázquez-Prado J, Gutkind JS, (2004) P-REX2, a novel PI-3-kinase sensitive Rac exchange factor. FEBS Lett 572: 167-171. doi:10.1016/j.febslet.2004.06.097. PubMed: 15304342.
30. Das B, Shu X, Day GJ, Han J, Krishna UM, et al. (2000) Control of intramolecular interactions between the pleckstrin homology and Dbl homology domains of Vav and Sos1 regulates Rac binding. J Biol Chem 275: 15074-15081. doi:10.1074/jbc.M907269199. PubMed: 10748082.
31. Hill K, Krugmann S, Andrews SR, Coadwell WJ, Finan P, et al. (2005) Regulation of P-Rex1 by phosphatidylinositol (3,4,5)-trisphosphate and Gbetagamma subunits. J Biol Chem 280: 4166-4173. PubMed: 15545267.
32. Chhatriwala MK, Betts L, Worthylake DK, Sondek J, (2007) The DH and PH domains of Trio coordinately engage Rho GTPases for their efficient activation. J Mol Biol 368: 1307-1320. doi:10.1016/j.jmb.2007.02.060. PubMed: 17391702.
33. Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, et al. (2010) Identification of the Rac-GEF P-Rex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell 40: 877-892. doi:10.1016/j.molcel.2010.11.029. PubMed: 21172654.
34. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M, (2010) KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 38: D355-D360. doi:10.1093/nar/gkp896. PubMed: 19880382.
35. Hecht JL, Mutter GL, (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24: 4783-4791. doi:10.1200/JCO.2006.06.7173. PubMed: 17028294.
36. Li C, Fang R, Sun Y, Han X, Li F, et al. (2011) Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLOS ONE 6: e28204. doi:10.1371/journal.pone.0028204. PubMed: 22140546.
37. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97: 339-346. doi:10.1093/jnci/dji055. PubMed: 15741570.
38. Sharma SV, Bell DW, Settleman J, Haber DA, (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181. doi:10.1038/nrc2088. PubMed: 17318210.
39. Bos JL, (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689. PubMed: 2547513.
40. Degen M, Brellier F, Kain R, Ruiz C, Terracciano L, et al. (2007) Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. Cancer Res 67: 9169-9179. doi:10.1158/0008-5472.CAN-07-0666. PubMed: 17909022.
41. Degen M, Brellier F, Schenk S, Driscoll R, Zaman K, et al. (2008) Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Int J Cancer 122: 2454-2461. doi:10.1002/ijc.23417. PubMed: 18306355.
42. Brellier F, Martina E, Degen M, Heuzé-Vourc'h N, Petit A, et al. (2012) Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors. BMC Clin Pathol 12: 14. doi:10.1186/1472-6890-12-14. PubMed: 22947174.
43. Dasika GK, Lin SC, Zhao S, Sung P, Tomkinson A, et al. (1999) DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18: 7883-7899. PubMed: 10630641.
44. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870. doi:10.1038/nature03482. PubMed: 15829956.
45. Yan X, Baxter RC, Firth SM, (2010) Involvement of pregnancy-associated plasma protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a potential mechanism for increasing IGF bioavailability. J Clin Endocrinol Metab 95: 1412-1420. doi:10.1210/jc.2009-2277. PubMed: 20103653.
46. Overgaard MT, Boldt HB, Laursen LS, Sottrup-Jensen L, Conover CA, et al. (2001) Pregnancy-associated plasma protein-A2 (PAPP-A2), a novel insulin-like growth factor-binding protein-5 proteinase. J Biol Chem 276: 21849-21853. doi:10.1074/jbc.M102191200. PubMed: 11264294.
47. Shimasaki S, Shimonaka M, Zhang HP, Ling N, (1991) Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human. J Biol Chem 266: 10646-10653. PubMed: 1709938.
48. Su Y, Wagner ER, Luo Q, Huang J, Chen L, et al. (2011) Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene 30: 3907-3917. doi:10.1038/onc.2011.97. PubMed: 21460855.
49. Huang T, Jiang M, Kong X, Cai YD, (2012) Dysfunctions associated with methylation, microRNA expression and gene expression in lung cancer. PLOS ONE 7: e43441. doi:10.1371/journal.pone.0043441. PubMed: 22912875.
50. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079. doi:10.1093/bioinformatics/btp352. PubMed: 19505943.
51. Fujimoto A, Nakagawa H, Hosono N, Nakano K, Abe T, et al. (2010) Whole-genome sequencing and comprehensive variant analysis of a Japanese individual using massively parallel sequencing. Nat Genet 42: 931-936. doi:10.1038/ng.691. PubMed: 20972442.
52. Quevillon E, Silventoinen V, Pillai S, Harte N, Mulder N, et al. (2005) InterProScan: protein domains identifier. Nucleic Acids Res 33: W116-W120. doi:10.1093/nar/gni118. PubMed: 15980438.